The Leishmaniasis East Africa Platform (LEAP): strengthening clinical trial capacity in resource-limited countries to deliver new treatments for visceral leishmaniasis
نویسندگان
چکیده
Visceral leishmaniasis is a neglected tropical disease endemic in East Africa where improved patient-adapted treatments are needed. The Leishmaniasis East Africa Platform (LEAP) was created in 2003 to strengthen clinical research capacity, serve as a base for training, and evaluate and facilitate implementation of new treatments. Major infrastructure upgrades and personnel training have been carried out. A short course of Sodium Stibogluconate and Paramomycin (SSG&PM) was evaluated and is now first-line treatment in the region; alternative treatments have also been assessed. LEAP can serve as a successful model of collaboration between different partners and countries when conducting clinical research in endemic countries to international standards.
منابع مشابه
Innovative Approaches to Clinical Data Management in Resource Limited Settings Using Open-Source Technologies
The primary objective of clinical data management (CDM) is to provide highquality, reliable data for reporting randomized controlled trials (RCTs) in line with good clinical practice (GCP) requirements. For treatment trials of neglected tropical diseases (NTDs) in endemic countries, CDM systems need to be efficient and affordable. Challenges include poor infrastructure, license costs associated...
متن کاملVisceral leishmaniasis in children
Background and Objectives: Visceral leishmaniasis is a chronic disease in Africa and Asia, children under 5 years are affecting with L.infantum and older children and young adult with L.donovani Purpose of this study describes the characteristics of epidemiologic and clinicopathophysiologic and response to treatment of patient that affected in East Azarbaijan compared with other endemic areas ...
متن کاملMiltefosine for visceral and cutaneous leishmaniasis: drug characteristics and evidence-based treatment recommendations.
Miltefosine is the only recognized oral agent with potential to treat leishmaniasis. Miltefosine had demonstrated very good cure rates for visceral leishmaniasis (VL) in India, Nepal, and Bangladesh, but high rates of clinical failures have been recently reported. Moderate efficacy has been observed for VL in East Africa, whereas data from Mediterranean countries and Latin America are scarce. R...
متن کاملManagement of trypanosomiasis and leishmaniasis
BACKGROUND The current treatments for human African trypanosomiasis (HAT), Chagas disease and leishmaniasis (collectively referred to as the kinetoplastid diseases) are far from ideal but, for some, there has been significant recent progress. For HAT the only advances in treatment over the past two decades have been the introduction of an eflornithine/nifurtimox co-administration and a shorter ...
متن کاملPlant-derived compounds in treatment of leishmaniasis
Leishmaniasis is a neglected public health problem caused by the protozoan species belonging to the genus Leishmania affecting mostly the poor populations of developing countries. The causative organism is transmitted by female sandflies. Cutaneous, mucocutaneous, and visceral clinical manifestations are the most frequent forms of leishmaniasis. Chemotherapy still relies on the use of pentavale...
متن کامل